News NRG announces £16m Series A for IND for Parkinson’s and ALS A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company
News Charity backs R&D into Parkinson's drugs targeting mitochond... The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
